AMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Truist Securities Reiterates Hold Rating on Amgen (AMGN), 'Competition for OX40 in atopic dermatitis narrowing'
March 29, 2022 10:42 AM EDTTruist Securities analyst Robyn Karnauskas reiterated a Hold rating and $263.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "Competition for OX40 in atopic dermatitis narrowing. This morning Sanofi (SNY;NR) highlighted their anti-OX40 ligand amlitelimab is a priority asset... More
